Indication
As monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
Medicine details
- Medicine name:
- zanubrutinib (Brukinsa)
- SMC ID:
- SMC2819
- Pharmaceutical company
- BeiGene UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Publication due date:
- 11 August 2025